As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial ...
We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
The MarketWatch News Department was not involved in the creation of this content. -- Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical ...
DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, announced a clinical trial collaboration with BioNTech to evaluate a novel immuno-oncology combination in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results